Immune checkpoint blockade (ICB) provides clinical benefit to a subset of patients with
cancer. However, existing biomarkers do not reliably predict treatment response across …

Serial circulating tumor DNA (ctDNA) monitoring is emerging as a non-invasive strategy to
predict and monitor immune checkpoint blockade (ICB) therapeutic efficacy across cancer …

Purpose: Decisions to continue or suspend therapy with immune checkpoint inhibitors are
commonly guided by tumor dynamics seen on serial imaging. However, immunotherapy …

Background Recent clinical results support the use of new immune checkpoint blockers
(ICB), such as anti-PD-1 (eg nivolumab and pembrolizumab) and anti-PD-L1 antibodies …

PURPOSE As immune checkpoint inhibitors (ICI) become increasingly used in frontline
settings, identifying early indicators of response is needed. Recent studies suggest a role for …

The utility of circulating tumor DNA (ctDNA) as a biomarker in patients with advanced
cancers receiving immunotherapy is uncertain. We therefore analyzed pretreatment (n= 978) …

Considerable interest surrounds the use of immune-checkpoint inhibitors in patients with
solid tumours following the demonstration of the impressive clinical efficacy of anti …

Abstract Purpose: Treatment with PD-(L) 1 blockade can produce remarkably durable
responses in patients with non–small cell lung cancer (NSCLC). However, a significant …

Background Assessment of therapeutic activity of drugs blocking immune checkpoints such
as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear …

Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …